Compare 10X Genomics Inc (TXG) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Warner Music Group Corp — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Warner Music Group Corp trades at $28.2 (market cap $14.64B). The key difference: Warner Music Group Corp is far larger — about 2.7× 10X Genomics Inc's market cap, and Warner Music Group Corp pays a 2.71% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | WMG | |
|---|---|---|
Market Cap | $5.48B | $14.64B |
Sector | Health | Media |
52-Week High | $45.80 | $34.72 |
52-Week Low | $11.34 | $23.65 |
Enterprise Value | $5.02B | $18.84B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Warner Music Group (WMG) trades at $27.945, down 1.36% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but recent quarterly misses. Revenue growth is steady, reaching $6.71B in 2025, though net income margin has compressed to 5.44%. Recent strategic moves include a licensing renewal with NetEase Cloud Music and the acquisition of AI startup Sureel AI, positioning the company for growth in digital and AI-driven music markets.
WMG presents a compelling long-term opportunity with analyst consensus pointing to significant upside (target $41.00), supported by 66.66% buy ratings. However, risks include competitive pressures in streaming, margin volatility, and execution challenges in integrating AI technologies. The stock's current valuation multiples (P/E 33.4) suggest premium pricing relative to earnings, requiring sustained growth to justify investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
